Nicole Germino
Stock Analyst at Truist Securities
(3.64)
# 781
Out of 5,064 analysts
23
Total ratings
60%
Success rate
37.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Nicole Germino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Buy | $126 → $139 | $198.76 | -30.07% | 10 | Aug 14, 2025 | |
| CATX Perspective Therapeutics | Maintains: Buy | $10 → $8 | $2.09 | +282.78% | 3 | May 14, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $5 | $0.42 | +1,080.92% | 5 | Jan 23, 2025 | |
| ASMB Assembly Biosciences | Downgrades: Hold | $132 → $24 | $38.50 | -37.66% | 3 | Oct 24, 2022 | |
| FBRX Forte Biosciences | Downgrades: Hold | n/a | $18.42 | - | 2 | Sep 3, 2021 |
Insmed
Aug 14, 2025
Maintains: Buy
Price Target: $126 → $139
Current: $198.76
Upside: -30.07%
Perspective Therapeutics
May 14, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $2.09
Upside: +282.78%
Sangamo Therapeutics
Jan 23, 2025
Maintains: Buy
Price Target: $7 → $5
Current: $0.42
Upside: +1,080.92%
Assembly Biosciences
Oct 24, 2022
Downgrades: Hold
Price Target: $132 → $24
Current: $38.50
Upside: -37.66%
Forte Biosciences
Sep 3, 2021
Downgrades: Hold
Price Target: n/a
Current: $18.42
Upside: -